E-LIB Suche - Ergebnisse für: Barratt, Daniel T.

1

Pharmacokinetic and neuroimmune pharmacogenetic impacts on ..:

Barratt, Daniel T. ; Klepstad, Pål ; Dale, Ola..
The Pharmacogenomics Journal. 24 (2024) 3 - p. , 2024

Link: https://doi.org/10.1038/..

2

From blood markers to performance prediction: New insights ..:

Hutchinson, Mark ; Barratt, Daniel T. ; Holmes, Joshua...
Brain, Behavior, and Immunity. 114 (2023) - p. 45-46 , 2023

Link: https://doi.org/10.1016/..

3

Population Pharmacokinetics and Pharmacodynamics of the The..:

Abuhelwa, Ahmad Y. ; Somogyi, Andrew A. ; Loo, Colleen K....
Clinical Pharmacology & Therapeutics. 112 (2022) 3 - p. 720-729 , 2022

Link: https://doi.org/10.1002/..

4

New pharmacological perspectives and therapeutic options fo..:

Somogyi, Andrew A ; Musolino, Stefan T ; Barratt, Daniel T
Anaesthesia and Intensive Care. 50 (2022) 1-2 - p. 127-140 , 2022

Link: https://doi.org/10.1177/..

5

Instability of Efavirenz Metabolites Identified During Meth..:

Andriguetti, Natália Bordin ; Barratt, Daniel T. ; Tucci, Joseph..
Journal of Pharmaceutical Sciences. 110 (2021) 10 - p. 3362-3366 , 2021

Link: https://doi.org/10.1016/..

6

Innate Immune and Neuronal Genetic Markers Are Highly Predi..:

Barratt, Daniel T ; Sia, Alex T ; Tan, Ene-Choo.
Pain Medicine. 22 (2021) 11 - p. 2648-2660 , 2021

Link: https://doi.org/10.1093/..

7

Tacrolimus dose, blood concentrations and acute nephrotoxic..:

Sallustio, Benedetta C. ; Noll, Benjamin D. ; Hu, Rong...
British Journal of Clinical Pharmacology. 87 (2021) 10 - p. 3901-3909 , 2021

Link: https://doi.org/10.1111/..

8

No Major Effect of Innate Immune Genetics on Acute Kidney R..:

Hu, Rong ; Barratt, Daniel T. ; Coller, Janet K...
Frontiers in Pharmacology. 10 (2020) - p. , 2020

Link: https://doi.org/10.3389/..

9

Effect of tacrolimus dispositional genetics on acute reject..:

Hu, Rong ; Barratt, Daniel T. ; Coller, Janet K...
Pharmacogenetics and Genomics. 29 (2019) 1 - p. 9-17 , 2019

Link: https://doi.org/10.1097/..

10

High and variable population prevalence of HLA‐B*56:02 in i..:

Somogyi, Andrew A. ; Barratt, Daniel T. ; Phillips, Elizabeth J....
British Journal of Clinical Pharmacology. 85 (2019) 9 - p. 2163-2169 , 2019

Link: https://doi.org/10.1111/..

11

Pharmacogenomics in Papua New Guineans: unique profiles and..:

Tucci, Joseph D. ; Pumuye, Paul P. ; Helsby, Nuala A....
Pharmacogenetics and Genomics. 28 (2018) 6 - p. 153-164 , 2018

Link: https://doi.org/10.1097/..

12

CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose‐adjus..:

Hu, Rong ; Barratt, Daniel T. ; Coller, Janet K...
Basic & Clinical Pharmacology & Toxicology. 123 (2018) 3 - p. 320-326 , 2018

Link: https://doi.org/10.1111/..

13

CYP2C8 Genotype Significantly Alters Imatinib Metabolism in..:

Barratt, Daniel T. ; Cox, Hannah K. ; Menelaou, Andrew...
Clinical Pharmacokinetics. 56 (2016) 8 - p. 977-985 , 2016

Link: https://doi.org/10.1007/..

14

Innate Immune Signalling Genetics of Pain, Cognitive Dysfun..:

Barratt, Daniel T. ; Klepstad, Pål ; Dale, Ola...
PLOS ONE. 10 (2015) 9 - p. e0137179 , 2015

Link: https://doi.org/10.1371/..

15

Genetic, pathological and physiological determinants of tra..:

Barratt, Daniel T. ; Bandak, Benedikte ; Klepstad, Pål...
Pharmacogenetics and Genomics. 24 (2014) 4 - p. 185-194 , 2014

Link: https://doi.org/10.1097/..